⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2026Lara D. Veeken

P026 Dose optimisation in rheumatology high-cost drug patients

Rachel Macmillan Janet Ball Alex Vincent

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the effects of dose optimisation on stable patients using biologic therapies for inflammatory arthritis.
Included patients on biologic therapies in remission for twelve months.
Increased injection intervals by approximately 30% every three months up to four steps.
Reviewed patient progress every three months with the option to return to previous dosing.
47% of eligible patients were successfully dose optimised over two years.
Achieved cumulative savings of £746,005.98 by reducing medication use.
Patients at various steps: 48 at Step 1, 81 at Step 2, 44 at Step 3, and 24 at Step 4.

Implication

Explores dose optimisation in patients, indicating significant cost savings and improved management.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Macmillan et al. (2026) studied this question.

synapsesocial.com/papers/69f2f2221e5f7920c6387a00 https://doi.org/10.1093/rheumatology/keag121.062

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1AB1349 BIOLOGIC AND TARGETED SYNTHETIC DRUGS MANAGEMENT IN RHEUMATOID ARTHRITIS AFTER IMPLEMENTATION OF A COMMUNITY OPTIMIZATION PROTOCOL2024
2AB0557 BIOLOGICAL THERAPY OPTIMIZATION IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS. ANALYSIS OF EFFECTIVENESS IN A COHORT OF PATIENTS IN CLINICAL PRACTICE CONDITIONS2024
3REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patientsNarrative Review · 2017 · 8 citations
4P029 Reducing delays in homecare biologics prescribing in a Rheumatology department: a single-centre quality improvement projectOriginal Research · 2026
5E054 Rituximab dose minimisation in rheumatoid arthritis, a retrospective outcome analysis2024

OA24 Annual prescribing of biologic agents: a six-month audit of implementation and safety at Guy’s and St Thomas’ Rheumatology2026
E020 Biologic withdrawal in seronegative arthritis: safe and cost-effective2026
P053 Sub-optimal response to first biologic in axial spondyloarthritis: real world data showing clinician decisions in a tertiary centre2024
Extra-renal disease patterns in lupus nephritis: clinical and serological activity confers increased risk of renal flares and damage accrualLara D. Veeken · 2026
Predictors of b/tsDMARDs discontinuation and treatment response in psoriatic arthritis: results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA)Lara D. Veeken · 2026

More from Lara D. Veeken

More from Royal National Hospital for Rheumatic Diseases